The coronavirus pandemic has placed unprecedented burdens on cord blood and perinatal tissue investigations, but it has not sent those studies into quarantine. That’s immediately evident when scanning the agenda for this year’s Cord Blood Connect international congress.
Resourceful investigators have been pushing forward on their clinical trials and laboratory studies. They will be bringing results and status reports to the virtual congress that is scheduled for two consecutive Thursdays, Sept. 23 and 30.
“We are thrilled to bring to congress attendees a scientific program that is relevant to all that is happening in 2021 and beyond,” said Ngaire Elwood, PhD, chair of the Scientific Program Committee. “There will be plenty of opportunity for interaction and discussion on the topics presented, with moderated Q&A time at the end of each session.”
Among the sessions will be:
- Advances in cord blood transplantation for leukemia
- Beyond ex-vivo expansion for malignant and non-malignant diseases
- Cord blood transplant outcomes: Clinical and economic perspectives
- Critical aspects of MSC manufacturing for clinical use
- Emerging therapies and regenerative medicine: Development of safe and effective products
- Cord blood and the treatment of sickle cell disease and other hemoglobinopathies
- Immune-modulating cell therapies
- Oral presentation of the Best Abstracts
Click here for the agenda that includes individual presentations and presenters.
Click here to register for the two days of live-stream webcasts and unlimited access to all congress components for 12 months. All sessions, e-posters and virtual exhibits will be recorded and remain available to registrants through August next year.
The $160 USD registration fee is waived for CBA members who register by Aug. 31. If you aren’t a CBA member, or your membership has lapsed, you can join or renew when registering and the congress fee will be waived. CBA individual member annual dues are $99 USD.